We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The House voted to pass a short-term funding measure to keep the government running through Dec. 11 at fiscal 2020 funding levels for fiscal 2021, which begins Oct. 1. Read More
In a Senate hearing yesterday, Anthony Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases, said that “some time by November or December we will know” which of the three COVID-19 vaccine candidates now in late-stage trials — soon to be joined by a fourth — are safe and effective. Read More
In a proposed rule released yesterday, the FDA clarifies how it determines whether products are intended for use as drugs or devices and how it decides if approved products are intended for a new use. Read More
The House of Representatives on Monday passed three bipartisan pharma bills, all by voice votes, aimed at promoting continuous drug manufacturing, the release of drugs from the Strategic National Stockpile and extending the FDA’s authority for counterfeit products. Read More
HHS has clarified that last week’s memo from Secretary Alex Azar will in no way impact the FDA’s decisions on drugs and vaccines although former FDA officials say questions remain. Read More
Coronavir, a treatment developed by Russian company R-Pharm for mild-to-moderate COVID-19 infections, is slated to be offered in pharmacies in that country as early as this week. Read More
HHS on Sunday refuted reports that a new departmental memo will take decision-making power away from the FDA regarding the approval of COVID-19 vaccines or therapeutics. Read More
Despite industry resistance and reluctance from state legislatures, the Trump administration is gearing up to issue a final rule allowing states to import prescription drugs from Canada as part of its campaign to deliver lower drug prices. Read More
Leaders of the House Energy and Commerce committee on Friday lashed out at the Trump administration for allegedly blocking Commissioner Stephen Hahn from testifying about the agency’s COVID-19 response. Read More
The Center for American Progress (CAP), a Democrat-aligned think tank, issued a report Thursday recommending how the next president could lower drug prices, such as by leveraging existing laws to break up drug monopolies. Read More
FDA’s Office of Prescription Drug Promotion (ODOP) slapped Sprout Pharmaceuticals with a warning letter over the misbranding of its drug Addyi (flibanserin) in a direct-to-consumer radio ad. Read More